ABSTRACT
OBJECTIVE:To investigate the effects of Tongxinluo capsules on the levels of serum cyclophilin A (CyPA) and matrix metalloproteinase-9 (MMP-9) in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).METHODS:A total of 115 CHD patients undergoing PCI were randomly divided into control group (59 cases) and observation group (56 cases).Control group was given conventional treatment.Observation group was additionally given Tongxinluo capsules 0.78 g,3 times a day,for consecutive 6 months,on the basis of control group.The levels of CyPA and MMP-9 as well as the occurrence of ADR were observed in 2 groups before and after treatment.RESULTS:Before treatment,there was no statistical significance in serum level of CyPA and MMP-9 between 2 groups (P＞0.05).The levels of CyPA in 2 groups 1 d and 1 month after surgery as well as the level of CyPA in control group 6 months after surgery were all significantly higher than before surgery,but the observation group was significantly lower than the control group 1 and 6 months,this index was decreased gradually as time,with statistical significance (P＜0.05).There was no statistical significance in the levels of CyPA between 2 groups 1 d after surgery or in observation group between 6 months after surgery and before surgery (P＞0.05).The levels of MMP-9 in 2 groups 1 d and 1 month after surgery were significantly higher than before surgery,and the observation group was significantly lower than the control group,this index was decreased gradually as time,with statistical significance (P＜0.05).There was no statistical significance in the levels of MMP-9 of 2 groups between 6 months after surgery and before surgery(P＞0.05).There was no statistical significance in the incidence of ADR between 2 groups (P＞0.05).CONCLUSIONS:Based on routine treatment,Tongxinluo capsules can significantly reduce the levels of CyPA and MMP-9 in CHD patients after PCI.
ABSTRACT
Objective: To observe and analyze clinical characteristics of patients with coronary myocardial bridge (CMB) and explore its therapeutic methods. Methods: To retrospectively analyze clinical data of 340 patients undergoing selective coronary angiography (CAG) in our hospital from Jan 2011 to Jan 2013. Results: A total of 33 CMB cases (9.7%) were found in 340 patients undergoing CAG, including 29 cases（87.9%）with isolated myocardial bridge and four patients with coronary atherosclerosis-like changes. There were 31 cases (93.9%) located in left anterior descending branch (LAD), one case (3.03%) in the first diagonal branch (D1) and one case (3.03%) in left circumflex artery (LCX). According to Noble classification of stenosis, 19 cases (57.6%) were class 1, 12 cases (36.4%) were class 2 and two cases (6.06%) were class 3. A total of 16 cases (48.5%) had typical symptoms of angina pectoris, 15 cases (45.5%) had chest tightness and two cases (6.06%) had palpitations. In electrocardiogram and/or dynamic electrocardiogram, ST-T or T wave changes were found in 19 cases (57.6%). All patients received β-receptor blocker and/or non-dyhydropyridine calcium channel blocker, and 29 patients (87.7%) with symptoms improved. Conclusion: Clinical symptoms and manifestations of myocardial bridge is diverse, β-receptor blocker and non-dyhydropyridine calcium channel blocker can relieve most clinical symptoms caused by myocardial bridge.